WHO Releases Consolidated Guidelines on Tuberculosis Preventive Treatment 2026

The updated normative guidelines detail programmatic scale-up in South-East Asia and Sub-Saharan Africa, integrating 1HP/3HP rifapentine-based regimens and point-of-care digital diagnostics for primary health care centers.

Executive Policy Digest & Programmatic Directives

The World Health Organization explicitly deprecates the standalone routine reliance on 6-month and 9-month daily isoniazid monotherapy (6H/9H) across public health units where rifapentine supplies are established. Health systems in high-burden Low- and Middle-Income Countries (LMICs) are mandated to prioritize ultra-short 1-month daily (1HP) and 3-month weekly (3HP) rifapentine-based regimens. Universal screening must be coupled with CAD (Computer-Aided Detection) AI-integrated ultra-portable digital chest X-ray platforms at peripheral health posts to exclude active TB before TPT initiation.

1. Context & Epidemiological Urgency in South Asia

Tuberculosis continues to represent one of the leading infectious disease causes of morbidity and mortality across the WHO South-East Asia Region. Despite substantial investments in diagnostic infrastructure and directly observed therapy short-course (DOTS), transmission chains remain sustained by massive latent reservoirs. Mathematical modeling published in The Lancet Infectious Diseases reveals that upwards of 28% of the adult population in Nepal, Bangladesh, and Northern India harbor latent Mycobacterium tuberculosis infection.

Prior international guidelines faced persistent bottlenecks at sub-national levels: the long duration of six-month daily isoniazid monotherapy (6H) led to severe treatment default rates (frequently exceeding 45% in rural outposts) and unmonitored drug-induced hepatotoxicity. The WHO 2026 Consolidated Guidelines formally reframe latent TB management not as an auxiliary clinic project, but as an indispensable pillar alongside active transmission interruption.

• 92% completion rate with 3HP (vs 54% historic completion for 6H regimens)
• 38% reduction in liver injury — statistically verified lower hepatotoxicity markers
• 12-week course duration target — once-weekly fixed-dose combination dosing

2. Key Regimen Updates: 1HP and 3HP vs 6H Monotherapy

The normative shift pivots programmatic protocols from extended daily regimens to short-course rifamycin-containing alternatives:

• 1HP: Daily Rifapentine + Isoniazid, daily x 28 doses (1 month) — ages 13+, PLHIV, household contacts — Strong recommendation
• 3HP: Weekly Rifapentine + Isoniazid FDC, once weekly x 12 doses (3 months) — adults & children 2+ years — Preferred first-line
• 3HR: Daily Isoniazid + Rifampicin, daily x 12 weeks — pediatric contacts under 2 years, areas lacking rifapentine — Conditional alternative
• 6H/9H: Daily isoniazid monotherapy — restricted to rifamycin intolerance — phased deprecation

Pharmacological co-administration alert: When initiating rifapentine-based TPT in people living with HIV (PLHIV), clinicians must note that rifapentine induces cytochrome P450 3A4 enzymes. Dolutegravir (DTG) dosing must be adjusted to 50mg twice daily in patients receiving 1HP, whereas no dose adjustment is mandated during once-weekly 3HP administration.

3. Diagnostic Algorithms & Ultra-Portable Digital X-Ray + AI Integration

A foundational prerequisite of preventative therapy is the unequivocal exclusion of active TB disease to prevent inadvertent monotherapy and subsequent rifamycin drug resistance. The 2026 framework mandates that national health programmes deploy Computer-Aided Detection (CAD) artificial intelligence software calibrated to regional chest pathology baselines.

1. Stage 01 — Symptom screen: evaluation for current cough, fever, night sweats, or hemoptysis at intake.
2. Stage 02 — Portable CXR + CAD: threshold score below 0.45 excludes active TB; score 0.45 or above routes to molecular test.
3. Stage 03 — GeneXpert / Truenat: rapid molecular sputum verification for CAD-positive or symptomatic subjects.
4. Stage 04 — TPT dispensing: enrollment into 3HP/1HP cohort with digital adherence SMS link.

4. Special Populations: Children, People Living with HIV (PLHIV), and Close Contacts

• Pediatric household contacts (under 5 years): immediate evaluation upon adult index identification. In children under 2 years where rifapentine formulations are currently unapproved, 3-month daily isoniazid and rifampicin (3HR) remains the operational standard.
• People living with HIV on second-line ART: routine annual screening; TPT indicated irrespective of CD4 counts once active pulmonary or extrapulmonary TB is excluded via rapid microbiological testing.
• Health care workers & prison populations: institutional biannual screening with prioritized 1HP regimens to sustain critical public sector operations and avoid nosocomial transmission corridors.

5. Supply Chain & Storage Requirements for Rifapentine

Rifapentine-based products display susceptibility to temperature excursions exceeding 30°C and relative humidity levels above 70%. For district warehouses in tropical and subtropical regions such as the Terai lowlands in Nepal and the Gangetic plains, the Global Drug Facility (GDF) recommends validated cold-chain monitoring.

• Temperature thresholds: store strictly between 20°C to 25°C; temporary excursions permitted up to 30°C for a maximum of 72 hours.
• Packaging stability: dispensed solely in tropical aluminum-aluminum blister packs; never decant into unsealed standard amber bottles.

6. MoHP Nepal National Strategic Alignment & Rollout Timeline

In formal concurrence with the WHO directive, the Ministry of Health and Population (MoHP) through the National Tuberculosis Control Centre (NTCC) in Bhaktapur has updated the National Strategic Plan for TB (NSP 2026-2031):

• Q1 2026 — Completed: standard operating procedures finalization; harmonization of clinical dosing algorithms and training module release via Nepal Public Health Academy.
• Q3 2026 — Active phase: priority procurement and pilot distribution of 120,000 courses of 3HP across 25 high-prevalence districts in Koshi, Madhesh, and Bagmati provinces.
• Q2 2027 — Target deadline: universal nationwide decentralization; 100% programmatic replacement of 6H at all 753 local-level primary health care centres.

Direct Resource Downloads & Annexures

• Annex 1: Clinical dosing chart by weight band — pediatric & adult dosing tables (1.4 MB PDF)
• Annex 2: District TB register & e-reporting — DHIS2 & e-TB tracker template (840 KB XLSX)
• Annex 3: Patient counseling & adverse protocol — pharmacovigilance card, English/Nepali (2.1 MB PDF)

“Tuberculosis preventive treatment is not merely an optional prophylactic precaution; it is an undeniable health right for household contacts, immunocompromised individuals, and high-risk health workers. We cannot achieve the End TB Strategy goals by waiting for transmission to turn into active disease. 2026 marks the year we pivot from reactive crisis treatment to preemptive population protection.”

Dr. Tereza Kasaeva, MD, PhD — Director, WHO Global Tuberculosis Programme, Geneva

Formal citation (Vancouver)

World Health Organization. WHO consolidated guidelines on tuberculosis: Module 1: Prevention — Tuberculosis preventive treatment. Geneva: World Health Organization; 2026. Licence: CC BY-NC-SA 3.0 IGO. Ref: WHO/UCN/TB/2026.04. DOI: 10.2471/TBR.2026.0142.

Synthesized, fact-checked, and localized in close collaboration with the National Tuberculosis Control Centre (NTCC), Ministry of Health and Population, Thimi, Bhaktapur. Document identifier WHO/HTM/TB/2026.12; effective immediately with programmatic rollout by Q2 2027.